Bengaluru: Biocon Biologics said on Tuesday that the US Food and Drug Administration (US FDA) has approved the company’s first-to-file application for Yesafili, a biosimilar drug for treating eye ailments. The company said the medicine is similar to the reference product Eylea (aflibercept) intended for the treatment of neovascular age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion, visual impairment due to diabetic macular oedema and visual impairment due to myopic choroidal neovascularisation. Studies demonstrate that Yesafili matches Eylea in quality, safety, and efficacy, it added. “The FDA approval of Yesafili (aflibercep
Hence then, the article about biocon biologics gets us fda nod for biosimilar version of eye treatment drug eylea was published today ( ) and is available onNews room odisha ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Biocon Biologics gets US FDA nod for biosimilar version of eye treatment drug Eylea )